Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit

The ubiquitin‐proteasome system (UPS) is an established therapeutic target for approved drugs to treat selected hematologic malignancies. While drug discovery targeting the UPS focuses on irreversibly binding epoxyketones and slowly‐reversibly binding boronates, optimization of novel covalent‐revers...

Descripción completa

Detalles Bibliográficos
Autores principales: Stubba, Daniel, Bensinger, Dennis, Steinbacher, Janika, Proskurjakov, Lilia, Salcedo Gómez, Álvaro, Schmidt, Uwe, Roth, Stefan, Schmitz, Katja, Schmidt, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916368/
https://www.ncbi.nlm.nih.gov/pubmed/31675179
http://dx.doi.org/10.1002/cmdc.201900472
_version_ 1783480224575389696
author Stubba, Daniel
Bensinger, Dennis
Steinbacher, Janika
Proskurjakov, Lilia
Salcedo Gómez, Álvaro
Schmidt, Uwe
Roth, Stefan
Schmitz, Katja
Schmidt, Boris
author_facet Stubba, Daniel
Bensinger, Dennis
Steinbacher, Janika
Proskurjakov, Lilia
Salcedo Gómez, Álvaro
Schmidt, Uwe
Roth, Stefan
Schmitz, Katja
Schmidt, Boris
author_sort Stubba, Daniel
collection PubMed
description The ubiquitin‐proteasome system (UPS) is an established therapeutic target for approved drugs to treat selected hematologic malignancies. While drug discovery targeting the UPS focuses on irreversibly binding epoxyketones and slowly‐reversibly binding boronates, optimization of novel covalent‐reversibly binding warheads remains largely unattended. We previously reported α‐ketoamides to be a promising reversible lead motif, yet the cytotoxic activity required further optimization. This work focuses on the lead optimization of phenoxy‐substituted α‐ketoamides combining the structure‐activity relationships from the primed and the non‐primed site of the proteasome β5 subunit. Our optimization strategy is accompanied by molecular modeling, suggesting occupation of P1′ by a 3‐phenoxy group to increase β5 inhibition and cytotoxic activity in leukemia cell lines. Key compounds were further profiled for time‐dependent inhibition of cellular substrate conversion. Furthermore, the α‐ketoamide lead structure 27 does not affect escape response behavior in Danio rerio embryos, in contrast to bortezomib, which suggests increased target specificity.
format Online
Article
Text
id pubmed-6916368
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69163682019-12-17 Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit Stubba, Daniel Bensinger, Dennis Steinbacher, Janika Proskurjakov, Lilia Salcedo Gómez, Álvaro Schmidt, Uwe Roth, Stefan Schmitz, Katja Schmidt, Boris ChemMedChem Full Papers The ubiquitin‐proteasome system (UPS) is an established therapeutic target for approved drugs to treat selected hematologic malignancies. While drug discovery targeting the UPS focuses on irreversibly binding epoxyketones and slowly‐reversibly binding boronates, optimization of novel covalent‐reversibly binding warheads remains largely unattended. We previously reported α‐ketoamides to be a promising reversible lead motif, yet the cytotoxic activity required further optimization. This work focuses on the lead optimization of phenoxy‐substituted α‐ketoamides combining the structure‐activity relationships from the primed and the non‐primed site of the proteasome β5 subunit. Our optimization strategy is accompanied by molecular modeling, suggesting occupation of P1′ by a 3‐phenoxy group to increase β5 inhibition and cytotoxic activity in leukemia cell lines. Key compounds were further profiled for time‐dependent inhibition of cellular substrate conversion. Furthermore, the α‐ketoamide lead structure 27 does not affect escape response behavior in Danio rerio embryos, in contrast to bortezomib, which suggests increased target specificity. John Wiley and Sons Inc. 2019-11-12 2019-12-04 /pmc/articles/PMC6916368/ /pubmed/31675179 http://dx.doi.org/10.1002/cmdc.201900472 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Stubba, Daniel
Bensinger, Dennis
Steinbacher, Janika
Proskurjakov, Lilia
Salcedo Gómez, Álvaro
Schmidt, Uwe
Roth, Stefan
Schmitz, Katja
Schmidt, Boris
Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
title Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
title_full Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
title_fullStr Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
title_full_unstemmed Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
title_short Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
title_sort cell‐based optimization of covalent reversible ketoamide inhibitors bridging the unprimed to the primed site of the proteasome β5 subunit
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916368/
https://www.ncbi.nlm.nih.gov/pubmed/31675179
http://dx.doi.org/10.1002/cmdc.201900472
work_keys_str_mv AT stubbadaniel cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT bensingerdennis cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT steinbacherjanika cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT proskurjakovlilia cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT salcedogomezalvaro cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT schmidtuwe cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT rothstefan cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT schmitzkatja cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit
AT schmidtboris cellbasedoptimizationofcovalentreversibleketoamideinhibitorsbridgingtheunprimedtotheprimedsiteoftheproteasomeb5subunit